Compounds > 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
Page last updated: 2024-08-03 15:50:15

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

Description

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID44595079
CHEMBL ID4116008
SCHEMBL ID736734
MeSH IDM000602453

Synonyms (46)

Synonym
S3566
cerdulatinib
cerdulatinib [inn]
D1LXQ45S1O ,
5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-
4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
prt-062070
1198300-79-6
cerdulatinib [who-dd]
rvt-502
HY-15999
CS-3329
SCHEMBL736734
unii-d1lxq45s1o
cerdulatinib (prt062070)
AC-30243
prt062070
prt 062070
4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
gtpl8957
prt-2070
AKOS026750510
prt2070
4-(cyclopropylamino)-2-({4-[4-(ethanesulfonyl)piperazin-1-yl]phenyl}amino)pyrimidine-5-carboxamide
NCGC00386415-04
FT-0741914
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
cerdulatinib; prt062070; prt2070
EX-A2143
DB15499
Q27075860
prt2070; prt-2070; prt 2070; prt-062070; prt 062070; prt062070
BCP10681
SB16931
CHEMBL4116008 ,
4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide
cerdulatinib (prt2070)
YXB30079
C71670
DTXSID001115521
AS-56368
bdbm50468574
nsc825827
nsc800071
nsc-825827
nsc-800071

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency2.6212AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency26.8370AID1645841
GVesicular stomatitis virusPotency18.9991AID1645842
Interferon betaHomo sapiens (human)Potency6.7157AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency18.9991AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency18.9991AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency18.9991AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
NUAK family SNF1-like kinase 1Homo sapiens (human)IC500.0040AID1845556
Tyrosine-protein kinase JAK2Homo sapiens (human)IC500.0060AID1405293; AID1875944
Tyrosine-protein kinase JAK1Homo sapiens (human)IC500.0120AID1405292; AID1875947
Tyrosine-protein kinase JAK3Homo sapiens (human)IC500.0080AID1405291; AID1875945

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1875945Inhibition of JAK 3 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804		Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1405292Inhibition of JAK1 (unknown origin)2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
ISSN: 1520-4804		Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
AID1405293Inhibition of JAK2 (unknown origin)2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
ISSN: 1520-4804		Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
AID1405291Inhibition of JAK3 (unknown origin)2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
ISSN: 1520-4804		Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
AID1845556Inhibition of NUAK1 (unknown origin)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
ISSN: 1520-4804		Development and Therapeutic Potential of NUAKs Inhibitors.
AID1875944Inhibition of JAK 2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804		Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1875947Inhibition of JAK 1 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804		Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1345508Human colony stimulating factor 1 receptor (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345714Human Janus kinase 2 (Janus kinase (JakA) family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345760Human mitogen-activated protein kinase kinase kinase 9 (MLK subfamily)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345744Human Janus kinase 3 (Janus kinase (JakA) family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345876Human spleen associated tyrosine kinase (Syk family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345757Human Janus kinase 1 (Janus kinase (JakA) family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345885Human serine/threonine kinase 4 (MST subfamily)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345872Human tyrosine kinase 2 (Janus kinase (JakA) family)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
AID1345741Human NUAK family kinase 1 (NuaK subfamily)2014The Journal of pharmacology and experimental therapeutics, Dec, Volume: 351, Issue:3
ISSN: 1521-0103		The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (56.25)24.3611
2020's7 (43.75)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (18.75%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (68.75%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
bisindolylmaleimide iv
1
indoles;
maleimides		202220222.0low000001
whi p154
1
201820186.0low000010
leflunomide
1
(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor		202220222.0low000001
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
1
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		202220222.0low000001
olomoucine
1
2,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor202220222.0low000001
tyrphostin a9
1
alkylbenzenegeroprotector202220222.0low000001
imatinib mesylate
1
methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		202220222.0low000001
gefitinib
1
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		202220222.0low000001
lestaurtinib
1
indolocarbazole202220222.0low000001
canertinib
1
monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		202220222.0low000001
cyc 202
1
2,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		202220222.0low000001
sb 203580
1
imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent		202220222.0low000001
erlotinib
1
aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor		202220222.0low000001
sorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		202220222.0low000001
pd 166326
1
202220222.0low000001
purvalanol a
1
purvalanol202220222.0low000001
s 1033
1
(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		202220222.0low000001
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol
2
substituted aniline201820224.0low000011
u 0126
1
aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent		202220222.0low000001
sf 2370
1
bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound		antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist		201820186.0low000010
dasatinib
1
1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		202220222.0low000001
alsterpaullone
1
C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor		202220222.0low000001
genistein
1
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		202220222.0low000001
rottlerin
1
aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite		202220222.0low000001
alvocidib
1
dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		202220222.0low000001
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
1
pyrimidines202220222.0low000001
bosutinib
1
aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor		202220222.0low000001
su 11248
2
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		202120222.5low000002
palbociclib
1
aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		202220222.0low000001
viroxime
1
202220222.0low000001
everolimus
1
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		202220222.0low000001
pd 184352
1
aminobenzoic acid202220222.0low000001
bibx 1382bs
1
substituted aniline202220222.0low000001
vacuolin-1
1
202220222.0low000001
pd 0325901
1
difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor		202220222.0low000001
midostaurin
1
benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		202220222.0low000001
tofacitinib
2
N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		201820224.0low000011
osu 03012
1
antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor		202220222.0low000001
bx795
2
ureas202120222.5low000002
azd 6244
1
benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor		202220222.0low000001
a 443654
1
indoles202220222.0low000001
apilimod
1
202220222.0low000001
jte 013
1
chloropyridine;
pyrazolopyridine		anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist		201820186.0low000010
pik 75
1
202220222.0low000001
saracatinib
1
aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent		202220222.0low000001
regorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor		202220222.0low000001
icg 001
1
peptide201820186.0low000010
bi 2536
1
202220222.0low000001
cc-930
1
201820186.0medium000010
crizotinib
1
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		202220222.0low000001
trametinib
1
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		202220222.0low000001
pha 767491
1
pyrrolopyridine202220222.0low000001
dactolisib
1
imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor		202220222.0low000001
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
organochlorine compound202220222.0low000001
gsk 461364
1
(trifluoromethyl)benzenes202120213.0low000001
nvp-tae684
1
piperidines202120213.0low000001
azd8330
1
pyridinecarboxamide202220222.0low000001
fedratinib
2
sulfonamide202120222.5low000002
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
1
202220222.0low000001
pci 32765
1
acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		202220222.0low000001
mk 2206
1
organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor202220222.0low000001
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		202220222.0low000001
incb-018424
1
nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		202220222.0low000001
fit-039
1
202220222.0low000001
azd2014
1
202220222.0low000001
bay 869766
1
202220222.0low000001
baricitinib
1
azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent		202220222.0low000001
mrt67307
1
aromatic amine202120213.0low000001
thiopental sodium
1
organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor		202120213.0low000001
bay 1000394
1
202120213.0low000001
ly2784544
1
pyridazines202220222.0low000001
sb 1518
1
202220222.0low000001
dinaciclib
1
pyrazolopyrimidine202220222.0low000001
gilteritinib
1
aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		202220222.0low000001
glpg0634
1
202220222.0low000001
delgocitinib
1
azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide		anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		202220222.0low000001
incb039110
1
202220222.0low000001
on123300
1
202120213.0medium000001
vx-970
1
sulfonamide202220222.0low000001
pf-543
1
sulfonamide201820186.0low000010
wz4003
1
202120213.0medium000001
ldc4297
1
aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		202220222.0medium000001
hth-01-015
1
202120213.0medium000001
at 9283
1
202220222.0low000001
xav939
1
(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor201820186.0low000010
ag-879
1
202220222.0low000001
hesperadin
1
202220222.0low000001
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
adenine
1
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201720177.0low000010
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one
1
organic heterotetracyclic compound;
organofluorine compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor201820186.0low000010
pci 32765
1
acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		201720177.0low000010
incb-018424
1
nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		201820186.0low000010
piperidines
1
201720177.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0
1
202220222.0low000001
Acute Lymphoid Leukemia0
1
202120213.0low000001
Adjuvant Arthritis0
1
2014201410.0low000010
ATLL0
1
201820186.0low000010
Autoimmune Diabetes0
1
201820186.0low000010
B-Cell Chronic Lymphocytic Leukemia0
1
201720177.0low000010
B-Cell Lymphoma0
3
201420196.7low200030
B-Cell Prolymphocytic Leukemia0
1
201920195.0low100010
Cirrhosis0
1
201820186.0low000010
Congenital Zika Syndrome0
1
202020204.0low000010
Dermatitis, Atopic0
1
202120213.0low100001
Diabetes Mellitus, Type 10
1
201820186.0low000010
Diffuse Large B-Cell Lymphoma0
2
201520197.0low100020
Diffuse Mixed Small and Large Cell Lymphoma0
1
201920195.0low100010
Disease Exacerbation0
1
202120213.0low000001
Disease Models, Animal0
2
201420207.0low000020
Eczema, Atopic0
1
202120213.0low100001
Fibrosis0
1
201820186.0low000010
Hematologic Malignancies0
1
201920195.0low100010
Hematologic Neoplasms0
1
201920195.0low100010
Leukemia-Lymphoma, Adult T-Cell0
1
201820186.0low000010
Leukemia, Lymphocytic, Chronic, B-Cell1
1
201720177.0low000010
Leukemia, Prolymphocytic, B-Cell0
1
201920195.0low100010
Lymphoma, B-Cell0
3
201420196.7low200030
Lymphoma, Large B-Cell, Diffuse0
2
201520197.0low100020
Lymphoma, Non-Hodgkin0
1
201920195.0low100010
Precursor Cell Lymphoblastic Leukemia-Lymphoma0
1
202120213.0low000001
Viral Diseases0
1
202220222.0low000001
Virus Diseases0
1
202220222.0low000001
Zika Virus Infection0
1
202020204.0low000010

Pharmacokinetics (1)

ArticleYear
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 25, Issue:4		2019

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019

Dosage (3)

ArticleYear
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 25, Issue:4		2019
Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
International journal of oncology, , Volume: 53, Issue:4		2018
The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
The Journal of pharmacology and experimental therapeutics, , Volume: 351, Issue:3		2014